Phase 2 N=5 Supportive Care

Erector Spinae Plane Block for Uncomplicated Renal Colic

Renal Colic · Kidney Stone

Bottom Line

View on ClinicalTrials.gov: NCT05625802 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Oct 2025

Primary outcome: Primary: Participants Who Received a Second Parenteral Pain Medication in the Emergency Department (ED) — 0 Participants

Study Design & Population

Study type: Interventional
Phase: Phase 2
Interventions: Erector Spinae Plane Block (ESPB) (Procedure); Ropivacaine (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: University of Michigan
Primary completion: Jan 2024

Outcome Measures

Outcome	Result	p-value
PRIMARY Participants Who Received a Second Parenteral Pain Medication in the Emergency Department (ED)	—	—
SECONDARY Change in Pain	3.2; 1.8; 1.8	—
SECONDARY Rate of Admission to Hospital for Kidney Stones	2; 1	—
SECONDARY Rate of 24-hour and 72-hour Return to the Emergency Department (ED)	0; 0	—
SECONDARY Emergency Department Length of Stay	418	—
SECONDARY Safety Outcomes and Complications	0; 0; 0; 0; 0; 0	—

Summary

This research study is to determine how well the Erector Spinae Plane Block (ESPB) works for kidney stone pain and any possible side effects.

Eligibility Criteria

Inclusion Criteria

Imaging confirmation of urolithiasis on the index encounter or prior encounter within 7 days
Patient received one dose of parenteral pain medication in the emergency department (ED)

Exclusion Criteria

Pregnancy or breastfeeding
Prisoner or incarcerated individual
Therapeutic anticoagulation or coagulopathy.
Active treatment for urinary tract infection (either acute infection or chronic therapy)
Prior spinal surgery in the thoracic region
Allergy to local anesthetic or prior local anesthetic
Soft tissue infection overlying the injection site
Positive for coronavirus
Inability to communicate verbally or read/write in English
Currently taking strong CYP1A2 inhibitor (fluvoxamine, amiodarone, fluoroquinolones, etc.)
Glucose-6-phosphate dehydrogenase deficiency (G6PD)

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05625802). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.